Immatics N.V. IMTX
Updated: 17 Jun 2026
No signal published yet
We already track Immatics N.V. and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Immatics N.V.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Immatics N.V. free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In June 2026, Immatics presented updated clinical data at the ASCO Annual Meeting showing deep and durable responses for its PRAME-targeted therapies, anzu-cel and IMA401, in patients with advanced solid tumors. These results support the ongoing Phase 3 SUPRAME trial and the expansion of the company's oncology pipeline. The company also scheduled its 2026 Annual General Meeting for June 18.
What Firelda Watch includes for Immatics N.V.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Immatics N.V.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Immatics N.V. free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more